PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33389067-14	2021	Ponatinib (FGFR1 inhibitor) reversed the suppressive effects of miR-214 inhibition on lung injury and inflammation of VILI mice.	ponatinib	0-9	fibroblast growth factor receptor 1	Mus musculus	11-16	
22875613-4	2013	Ponatinib-treated Ba/F3 cells transformed by ZMYM2-FGFR1 and BCR-FGFR1 and the FGFR1OP2-FGFR1 positive KG1A cell line showed reduced proliferation and decreased survival when compared to control cells.	ponatinib	0-9	fibroblast growth factor receptor 1	Mus musculus	51-56	
32064608-4	2020	Cell/molecular biological and analytical chemistry methods were applied to investigate uptake kinetics/subcellular distribution, the role of lipid droplets (LDs) and lipoid microenvironment compartments in responsiveness of FGFR1-driven lung cancer cells towards ponatinib.	ponatinib	263-272	fibroblast growth factor receptor 1	Mus musculus	224-229	
28646488-3	2017	Since resistance to targeted therapies is a major reason for relapse, we developed FGFR1-overexpressing mouse and human cell lines that are resistant to the specific FGFR inhibitors AZD4547 and BGJ398, as well as non-specific inhibitors, such as ponatinib, TKI258 and E3810.	ponatinib	246-255	fibroblast growth factor receptor 1	Mus musculus	83-88	
28138694-0	2017	Activity of fibroblast growth factor receptor inhibitors TKI258, ponatinib and AZD4547 against TPR-FGFR1 fusion.	ponatinib	65-74	fibroblast growth factor receptor 1	Mus musculus	99-104	
28138694-4	2017	To identify the most promising drug for EMS, the activities and associated mechanism of three tyrosine kinase inhibitors (TKIs), TKI258, ponatinib and AZD4547, against TPR-FGFR1 were tested by MTT assay, flow cytometry and western blot.	ponatinib	137-146	fibroblast growth factor receptor 1	Mus musculus	172-177	
22875613-4	2013	Ponatinib-treated Ba/F3 cells transformed by ZMYM2-FGFR1 and BCR-FGFR1 and the FGFR1OP2-FGFR1 positive KG1A cell line showed reduced proliferation and decreased survival when compared to control cells.	ponatinib	0-9	fibroblast growth factor receptor 1	Mus musculus	65-70	
22238366-4	2012	In Ba/F3 cells engineered to express activated FGFR1-4, ponatinib potently inhibited FGFR-mediated signaling and viability with IC(50) values <40 nmol/L, with substantial selectivity over parental Ba/F3 cells.	ponatinib	56-65	fibroblast growth factor receptor 1	Mus musculus	47-54